GRI Bio Overview
- Founded
- 2009
- Status
- Private
- Employees
- 5
- Latest Deal Type
- Angel
- Latest Deal Amount
- $5.71M
GRI Bio General Information
Description
Developer of therapies created to treat inflammatory diseases. The company's cell-based therapies are developed to treat liver disease and autoimmunity deficiencies by targeting the regulation of NKT cells.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- 2223 Avenida De La Playa
- Suite 105
- La Jolla, CA 92037
- United States
GRI Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Angel (individual) | 07-Nov-2018 | $5.71M | 00.000 | Completed | Generating Revenue | |
| 2. Angel (individual) | Cancelled | Generating Revenue | ||||
| 1. Angel (individual) | 17-Apr-2015 | $4.38M | $4.38M | Completed | Generating Revenue |
GRI Bio Executive Team (4)
GRI Bio Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Abraham Van Wyk | Self | Board Member | 000 0000 |
| Albert Agro Ph.D | Self | Senior Vice President of Clinical Development, Board Member and Co-Founder | 000 0000 |
| Marc Hertz Ph.D | GRI Bio | Co-Founder, Chairman & Chief Executive Officer | 000 0000 |
| Vipin Chaturvedi Ph.D | GRI Bio | Chief Scientific Officer, Board Member and Co-Founder | 000 0000 |
GRI Bio Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial